Department of Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands.
J Antimicrob Chemother. 2011 Mar;66(3):650-6. doi: 10.1093/jac/dkq465. Epub 2010 Dec 1.
To assess risk factors for fluoroquinolone resistance in community-onset febrile Escherichia coli urinary tract infection (UTI).
A nested case-control study within a cohort of consecutive adults with febrile UTI presenting at primary healthcare centres or emergency departments during January 2004 through December 2009. Resistance was defined using EUCAST criteria (ciprofloxacin MIC >1.0 mg/L). Cases were subjects with fluoroquinolone-resistant E. coli, and controls those with fluoroquinolone-susceptible isolates. Multivariable logistic regression analysis was used to identify potential risk factors for fluoroquinolone resistance.
Of 787 consecutive patients, 420 had E. coli-positive urine cultures. Of these, 51 (12%) were fluoroquinolone resistant. Independent risk factors for fluoroquinolone resistance were urinary catheter [odds ratio (OR) 3.1; 95% confidence interval (CI) 0.9-11.6], recent hospitalization (OR 2.0; 95% CI 1.0-4.3) and fluoroquinolone use in the past 6 months (OR 17.5; 95% CI 6.0-50.7). Environmental factors (e.g. contact with animals or hospitalized household members) were not associated with fluoroquinolone resistance. Of fluoroquinolone-resistant strains, 33% were resistant to amoxicillin/clavulanate and 65% to trimethoprim/sulfamethoxazole; 14% were extended-spectrum β-lactamase (ESBL) positive compared with <1% of fluoroquinolone-susceptible isolates.
Recent hospitalization, urinary catheter and fluoroquinolone use in the past 6 months were independent risk factors for fluoroquinolone resistance in community-onset febrile E. coli UTI. Contact with animals or hospitalized household members was not associated with fluoroquinolone resistance. Fluoroquinolone resistance may be a marker of broader resistance, including ESBL positivity.
评估社区获得性发热性大肠埃希菌尿路感染(UTI)中氟喹诺酮类药物耐药的危险因素。
这是一项嵌套病例对照研究,在 2004 年 1 月至 2009 年 12 月期间,对因发热性 UTI 在基层医疗机构或急诊科就诊的连续成年患者队列进行了研究。使用 EUCAST 标准(环丙沙星 MIC>1.0mg/L)定义耐药性。病例组为氟喹诺酮类耐药大肠埃希菌,对照组为氟喹诺酮类敏感分离株。采用多变量逻辑回归分析确定氟喹诺酮类耐药的潜在危险因素。
在 787 例连续患者中,420 例有大肠埃希菌阳性尿液培养。其中,51 例(12%)为氟喹诺酮类耐药。氟喹诺酮类耐药的独立危险因素包括导尿管(比值比[OR] 3.1;95%置信区间[CI] 0.9-11.6)、近期住院(OR 2.0;95%CI 1.0-4.3)和过去 6 个月内氟喹诺酮类药物的使用(OR 17.5;95%CI 6.0-50.7)。环境因素(如与动物接触或住院家庭成员)与氟喹诺酮类耐药无关。氟喹诺酮类耐药株中,33%对阿莫西林/克拉维酸耐药,65%对复方磺胺甲噁唑耐药;14%为产超广谱β-内酰胺酶(ESBL)阳性,而氟喹诺酮类敏感分离株中这一比例<1%。
近期住院、导尿管和过去 6 个月内氟喹诺酮类药物的使用是社区获得性发热性大肠埃希菌 UTI 中氟喹诺酮类耐药的独立危险因素。与动物接触或住院家庭成员无关。氟喹诺酮类耐药可能是广泛耐药的标志物,包括 ESBL 阳性。